| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head-Down Tilt | 11 | 2022 | 24 | 3.610 |
Why?
|
| Intracranial Pressure | 10 | 2019 | 180 | 2.910 |
Why?
|
| Space Flight | 11 | 2022 | 158 | 2.620 |
Why?
|
| Brain Ischemia | 9 | 2015 | 292 | 1.950 |
Why?
|
| Weightlessness Simulation | 7 | 2021 | 24 | 1.850 |
Why?
|
| Stroke | 11 | 2016 | 1144 | 1.750 |
Why?
|
| Cerebral Hemorrhage | 9 | 2020 | 183 | 1.560 |
Why?
|
| Carbon Dioxide | 6 | 2018 | 313 | 1.460 |
Why?
|
| Intracranial Hypertension | 3 | 2018 | 119 | 1.380 |
Why?
|
| Cerebrovascular Circulation | 5 | 2018 | 471 | 1.170 |
Why?
|
| Astronauts | 4 | 2022 | 60 | 1.040 |
Why?
|
| Choroid Diseases | 2 | 2021 | 26 | 0.980 |
Why?
|
| Pseudotumor Cerebri | 2 | 2016 | 60 | 0.970 |
Why?
|
| Blood Coagulation Factors | 2 | 2017 | 59 | 0.960 |
Why?
|
| Adaptation, Physiological | 3 | 2020 | 360 | 0.930 |
Why?
|
| Intracranial Hemorrhages | 2 | 2017 | 121 | 0.910 |
Why?
|
| Bed Rest | 3 | 2022 | 23 | 0.910 |
Why?
|
| Papilledema | 2 | 2021 | 85 | 0.910 |
Why?
|
| Thrombolytic Therapy | 4 | 2015 | 257 | 0.760 |
Why?
|
| Anticoagulants | 4 | 2017 | 787 | 0.760 |
Why?
|
| Fibrinolytic Agents | 4 | 2015 | 324 | 0.740 |
Why?
|
| Plasma | 3 | 2017 | 158 | 0.730 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2015 | 163 | 0.700 |
Why?
|
| Retinal Diseases | 1 | 2021 | 179 | 0.670 |
Why?
|
| Vision, Ocular | 1 | 2019 | 157 | 0.660 |
Why?
|
| Jugular Veins | 2 | 2018 | 107 | 0.660 |
Why?
|
| Pupil | 1 | 2018 | 54 | 0.630 |
Why?
|
| Coagulants | 1 | 2017 | 8 | 0.620 |
Why?
|
| Blood Volume | 1 | 2018 | 100 | 0.620 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2020 | 95 | 0.610 |
Why?
|
| Cerebral Blood Volume | 1 | 2017 | 7 | 0.610 |
Why?
|
| Myocardial Stunning | 2 | 2014 | 21 | 0.610 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 3 | 2017 | 111 | 0.600 |
Why?
|
| Brain | 8 | 2020 | 4113 | 0.570 |
Why?
|
| Patient Care Team | 2 | 2015 | 795 | 0.560 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 292 | 0.550 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 502 | 0.540 |
Why?
|
| Optic Disk | 1 | 2016 | 54 | 0.540 |
Why?
|
| Intubation | 1 | 2015 | 40 | 0.520 |
Why?
|
| Hospital Mortality | 6 | 2020 | 1274 | 0.510 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2014 | 9 | 0.510 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 26 | 0.480 |
Why?
|
| Hematoma | 3 | 2020 | 160 | 0.480 |
Why?
|
| Nervous System Diseases | 2 | 2015 | 500 | 0.470 |
Why?
|
| Pneumonia, Aspiration | 1 | 2013 | 41 | 0.450 |
Why?
|
| Cross Infection | 2 | 2015 | 544 | 0.450 |
Why?
|
| Critical Care | 3 | 2014 | 770 | 0.440 |
Why?
|
| Weightlessness | 4 | 2022 | 72 | 0.440 |
Why?
|
| Tracheostomy | 1 | 2015 | 243 | 0.430 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 130 | 0.410 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2011 | 8 | 0.410 |
Why?
|
| Blood Coagulation Disorders | 2 | 2012 | 120 | 0.390 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 501 | 0.390 |
Why?
|
| Athletic Injuries | 1 | 2011 | 97 | 0.370 |
Why?
|
| Length of Stay | 2 | 2015 | 1900 | 0.370 |
Why?
|
| Neuroprotective Agents | 4 | 2016 | 215 | 0.340 |
Why?
|
| Albumins | 3 | 2017 | 258 | 0.340 |
Why?
|
| Warfarin | 1 | 2010 | 152 | 0.340 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2008 | 12 | 0.340 |
Why?
|
| Pneumonia | 1 | 2015 | 751 | 0.330 |
Why?
|
| Adult | 25 | 2021 | 77950 | 0.320 |
Why?
|
| Vasospasm, Intracranial | 2 | 2020 | 22 | 0.310 |
Why?
|
| Humans | 54 | 2022 | 261506 | 0.300 |
Why?
|
| Intraocular Pressure | 3 | 2017 | 146 | 0.300 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1148 | 0.300 |
Why?
|
| Myasthenia Gravis | 1 | 2008 | 99 | 0.290 |
Why?
|
| Male | 32 | 2021 | 123000 | 0.280 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 4314 | 0.280 |
Why?
|
| Spinal Puncture | 2 | 2015 | 63 | 0.260 |
Why?
|
| Antihypertensive Agents | 2 | 2018 | 395 | 0.250 |
Why?
|
| Inpatients | 2 | 2015 | 678 | 0.250 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 330 | 0.240 |
Why?
|
| Brain Edema | 2 | 2018 | 86 | 0.230 |
Why?
|
| Middle Aged | 22 | 2020 | 86204 | 0.230 |
Why?
|
| Gravity, Altered | 1 | 2022 | 2 | 0.230 |
Why?
|
| Hemodynamics | 2 | 2018 | 935 | 0.220 |
Why?
|
| Intracranial Aneurysm | 2 | 2013 | 123 | 0.210 |
Why?
|
| Female | 23 | 2021 | 141928 | 0.200 |
Why?
|
| Myoclonus | 1 | 2021 | 34 | 0.200 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 36 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 2 | 2014 | 55 | 0.190 |
Why?
|
| Vision Disorders | 2 | 2019 | 245 | 0.180 |
Why?
|
| Encephalitis | 1 | 2021 | 143 | 0.180 |
Why?
|
| Vasoconstriction | 1 | 2020 | 104 | 0.180 |
Why?
|
| Young Adult | 7 | 2018 | 21445 | 0.180 |
Why?
|
| Neurology | 3 | 2015 | 113 | 0.170 |
Why?
|
| Minnesota | 2 | 2017 | 93 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2020 | 82 | 0.170 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 10 | 0.170 |
Why?
|
| Reflex, Oculocardiac | 1 | 2018 | 5 | 0.160 |
Why?
|
| Sodium | 1 | 2020 | 353 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2016 | 12873 | 0.160 |
Why?
|
| Breath Holding | 1 | 2018 | 44 | 0.160 |
Why?
|
| Magnesium | 1 | 2019 | 160 | 0.160 |
Why?
|
| APACHE | 2 | 2008 | 93 | 0.160 |
Why?
|
| Imidazoline Receptors | 1 | 2018 | 3 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2021 | 6100 | 0.160 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 46 | 0.160 |
Why?
|
| Risk Factors | 9 | 2020 | 17523 | 0.160 |
Why?
|
| Hypertension | 2 | 2018 | 1503 | 0.160 |
Why?
|
| Neurophysiological Monitoring | 1 | 2018 | 23 | 0.160 |
Why?
|
| Cerebral Angiography | 2 | 2015 | 129 | 0.160 |
Why?
|
| Hypercapnia | 1 | 2017 | 26 | 0.150 |
Why?
|
| Spectrum Analysis | 1 | 2018 | 139 | 0.150 |
Why?
|
| Germany | 1 | 2017 | 111 | 0.150 |
Why?
|
| Accelerometry | 1 | 2017 | 63 | 0.150 |
Why?
|
| Rest | 1 | 2017 | 71 | 0.150 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2016 | 2 | 0.150 |
Why?
|
| Blood Pressure | 3 | 2019 | 1467 | 0.150 |
Why?
|
| Aged | 13 | 2020 | 70117 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 1303 | 0.140 |
Why?
|
| Intensive Care Units | 2 | 2013 | 717 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 29902 | 0.140 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 173 | 0.140 |
Why?
|
| Internationality | 1 | 2017 | 208 | 0.140 |
Why?
|
| Autoradiography | 2 | 2005 | 132 | 0.140 |
Why?
|
| Neuroscience Nursing | 1 | 2015 | 1 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2015 | 467 | 0.130 |
Why?
|
| Hospitals, Special | 1 | 2015 | 24 | 0.130 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2015 | 32 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 703 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2020 | 37905 | 0.130 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 56 | 0.130 |
Why?
|
| Comorbidity | 3 | 2017 | 2352 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2005 | 172 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2017 | 2803 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 7702 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 249 | 0.120 |
Why?
|
| Blood-Brain Barrier | 2 | 2005 | 238 | 0.120 |
Why?
|
| Therapeutic Occlusion | 1 | 2013 | 2 | 0.120 |
Why?
|
| Moyamoya Disease | 1 | 2014 | 42 | 0.120 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 68 | 0.120 |
Why?
|
| Emergency Medicine | 1 | 2015 | 134 | 0.120 |
Why?
|
| Parasympathetic Nervous System | 1 | 2013 | 26 | 0.120 |
Why?
|
| Cerebral Arteries | 2 | 2016 | 73 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.110 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 97 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1537 | 0.110 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2013 | 50 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 127 | 0.110 |
Why?
|
| Postural Balance | 1 | 2014 | 151 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 444 | 0.110 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.110 |
Why?
|
| Lung Diseases, Fungal | 1 | 2013 | 124 | 0.110 |
Why?
|
| Cerebellum | 1 | 2016 | 449 | 0.110 |
Why?
|
| Sympathetic Nervous System | 1 | 2013 | 159 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2018 | 1171 | 0.100 |
Why?
|
| Image Enhancement | 2 | 2005 | 561 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2005 | 592 | 0.100 |
Why?
|
| Cross-Over Studies | 3 | 2017 | 460 | 0.100 |
Why?
|
| Cognition | 1 | 2017 | 968 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 1863 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 367 | 0.100 |
Why?
|
| Thrombin Time | 1 | 2010 | 5 | 0.100 |
Why?
|
| Prothrombin Time | 1 | 2010 | 44 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2018 | 945 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 48 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2015 | 661 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 960 | 0.090 |
Why?
|
| Incidence | 3 | 2020 | 5673 | 0.090 |
Why?
|
| Acute Disease | 3 | 2012 | 2422 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2010 | 155 | 0.090 |
Why?
|
| Platelet Count | 1 | 2010 | 490 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 447 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 4938 | 0.080 |
Why?
|
| Water-Electrolyte Balance | 1 | 2008 | 104 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 698 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 551 | 0.080 |
Why?
|
| Vitamin K | 1 | 2008 | 54 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 598 | 0.080 |
Why?
|
| Pyridostigmine Bromide | 1 | 2008 | 15 | 0.080 |
Why?
|
| Blood Gas Analysis | 1 | 2008 | 100 | 0.080 |
Why?
|
| Fatigue | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Receptors, Cholinergic | 1 | 2008 | 84 | 0.080 |
Why?
|
| Vitamins | 1 | 2008 | 157 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 6009 | 0.080 |
Why?
|
| Prognosis | 5 | 2020 | 21713 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 12926 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2588 | 0.070 |
Why?
|
| Stents | 1 | 2013 | 1096 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2008 | 110 | 0.070 |
Why?
|
| Plasma Exchange | 1 | 2008 | 117 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2008 | 180 | 0.070 |
Why?
|
| Cerebral Veins | 2 | 2017 | 28 | 0.070 |
Why?
|
| Status Epilepticus | 1 | 2008 | 145 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2010 | 1544 | 0.070 |
Why?
|
| Adolescent | 3 | 2015 | 31252 | 0.070 |
Why?
|
| United States | 3 | 2017 | 15433 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 577 | 0.060 |
Why?
|
| Extraterrestrial Environment | 1 | 2022 | 8 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2014 | 1375 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 482 | 0.060 |
Why?
|
| Apoptosis | 1 | 2016 | 7591 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2594 | 0.050 |
Why?
|
| Biomarkers | 3 | 2020 | 5047 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2017 | 9244 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 330 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2008 | 1270 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2020 | 215 | 0.040 |
Why?
|
| Nucleoside Deaminases | 1 | 1999 | 33 | 0.040 |
Why?
|
| Flucytosine | 1 | 1999 | 30 | 0.040 |
Why?
|
| Yeasts | 1 | 1999 | 74 | 0.040 |
Why?
|
| Animals | 6 | 2018 | 59536 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 388 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 700 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 4744 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 53 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 204 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4849 | 0.040 |
Why?
|
| Prodrugs | 1 | 1999 | 217 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2017 | 18 | 0.040 |
Why?
|
| Lower Body Negative Pressure | 1 | 2017 | 2 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2017 | 27 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 120 | 0.040 |
Why?
|
| Disease Progression | 1 | 2008 | 6682 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 7551 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 187 | 0.030 |
Why?
|
| Posture | 1 | 2017 | 215 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2017 | 240 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 4320 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2015 | 32848 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 925 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 737 | 0.030 |
Why?
|
| Bacteria | 1 | 1999 | 611 | 0.030 |
Why?
|
| Environment | 1 | 2015 | 190 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 339 | 0.030 |
Why?
|
| Serum Albumin, Human | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 87 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2014 | 53 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2005 | 562 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 660 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 163 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 672 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 383 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 1648 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 430 | 0.030 |
Why?
|
| Otolaryngology | 1 | 2014 | 129 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2012 | 47 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 111 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 202 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2012 | 94 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1999 | 1616 | 0.020 |
Why?
|
| Sleep | 1 | 2014 | 413 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1999 | 1390 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2012 | 249 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2013 | 435 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2316 | 0.020 |
Why?
|
| Contrast Media | 2 | 2005 | 1472 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 1145 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 731 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 516 | 0.020 |
Why?
|
| Myocardium | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 4971 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2008 | 170 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 6086 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 898 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 1999 | 39 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2195 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 14889 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 1082 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 3890 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 1519 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1944 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 5395 | 0.010 |
Why?
|
| Mice | 1 | 1999 | 34495 | 0.000 |
Why?
|